1.1Base removal of carbamate
The first coupling uses the intermediate bearing the fluorenylmethoxycarbonyl carbamate. Piperidine removes the carbamate, and the liberated ring amine reacts with an activated carboxylic acid to form the final amide.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
The first coupling uses the intermediate bearing the fluorenylmethoxycarbonyl carbamate. Piperidine removes the carbamate, and the liberated ring amine reacts with an activated carboxylic acid to form the final amide.
The deprotected ring amine reacts with a heteroaryl sulfonyl chloride to form an N–S bond. A tertiary amine base captures the hydrogen chloride released during sulfonamide formation.
Pyridine-3-carboxylic acid supplies the monocyclic ring and the carbonyl linker. Activation of its carboxyl group enables the deprotected scaffold amine to form the pyridine-3-carboxamide.
Oxetane-3-carboxylic acid supplies the oxetane ring for coupling to the scaffold amine. The product has an amide carbonyl bonded to carbon 3 of the four-membered cyclic ether.
Cyclopropylamine undergoes reductive amination with a side-chain aldehyde. Reduction of the resulting imine gives a secondary amine with the cyclopropyl group directly bonded to nitrogen.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
An environmental analytical laboratory uses the IIb to VIIb to VIIIb sequence and the final amidation to prepare a reference standard for a selected DDR inhibitor. The laboratory purifies the product, determines its content by quantitative proton nuclear magnetic resonance, and prepares a gravimetric stock solution. Aliquots of the stock fortify wastewater extracts at several concentrations for matrix-matched liquid chromatography–mass spectrometry calibration.
The final coupling uses 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride and ethyl 2-cyano-2-(hydroxyimino)acetate to activate the selected carboxylic acid. The activated acid reacts with VIIIb in acetonitrile in the presence of triethylamine, which also releases the free amine when VIIIb enters as an acid salt. An aqueous wash removes the water-soluble carbodiimide-derived urea before purification of the amide.
An allyloxycarbonyl group protects the amine that remains masked during the first amidation. The resulting protected amide is treated with tetrakis(triphenylphosphine)palladium and phenylsilane to release the free amine. A thiol-functionalized scavenger captures residual palladium, and the recovered amine enters the final coupling with the selected acid.
The first amidation and deprotection supply a single stock of VIIIb for a 24-vial array. Each 2 mL vial receives 10 micromoles of VIIIb and 12 micromoles of a different carboxylic acid in a final reaction volume of 200 microliters. The array holds the final couplings at 30 °C for 2 hours, after which liquid chromatography–mass spectrometry measures residual VIIIb and detects the expected product in each vial.
A continuous-flow module connects the isolated VIIb feed to the batch vessel for the final amidation. Separate pumps deliver a solution of VIIb and a solution of trifluoroacetic acid to a static mixer followed by a fluoropolymer residence coil. The outlet discharges into a vented receiver, where gas from cleavage disengages and the amine salt accumulates. The recovered salt enters the batch vessel with enough base to release VIIIb for coupling.
A liquid handler prepares the reactions and sends diluted aliquots to liquid chromatography–mass spectrometry at programmed intervals. Control software tracks IIb, VIIb and VIIIb using expected ion masses and calibrated retention windows. When the current stage meets its conversion threshold, the controller starts the programmed workup and transfers the recovered intermediate to the next vessel. Runs that miss the threshold at the maximum hold time remain in their vessels for review.
R2 is cyclopropoxy. An ether oxygen links the R2 attachment site on X to a carbon of the cyclopropane ring.
R3 is —O—CH2—CH2—OH. The first oxygen connects X to the two-carbon chain, and the terminal oxygen forms a primary alcohol.
The heterocycloalkyl group is 1-acetylpiperidin-4-yl. Carbon 4 provides the attachment to X, and the ring nitrogen bears —C(O)—CH3.
R5 is methyl and R4 is hydrogen in the —CH2—NR4R5 side chain. The resulting —CH2—NH—CH3 group contains a secondary amine.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
Treatment of aniline (10) with carboxylic acids of formula R12COOH in the presence of a coupling agent such as HATU or EDAC and a base such as diisopropylethylaminde or triethylamine, and in a solvent such as tetrahydrofuran, dioxane, or dimethylformamide, at a temperature from about 0° C. to about 40° C. provides amides of formula (11).B · US 2014/0275079 A1 · ¶ 307
wherein R41 is selected from the group consisting of: NO2, NR20R22, halo, C1-C6 alkyl, C1-C6 haloalkyl, —O—C1-C6 alkyl, —O—C1-C6 haloalkyl, C1-C3 alkylene-OH, C1-C3 alkylene-C(O)OH, C1-C3 alkylene-C(O)O—C1-C4 alkyl, C2-C3alkenylene-O—C1-C3alkyl, —NHC(O)—C1-C3 alkyl, —NH—SO2—C1-C3 alkyl, —NH—SO2—C1-C3 haloalkyl, —SO2—NH2, —C(O)—NR20R22, and -L-R12, wherein L is absent or is —C1-C3alkylene-, —C2-C3alkenylene-, —NH—, —NH—C1-C3alkylene-, —NR26—, —NHS(O)2—, NHS(O)2—C1-C3alkylene-,B · US 2014/0275079 A1 · ¶
In certain embodiments, R10 is unsubstituted heteroaryl. In some such embodiments, the unsubstituted heteroaryl is benzimidazolyl or indolyl.B · US 2014/0275079 A1 · ¶
R3 is heteroaryl, 9 to 12 membered bicyclic aryl, napthalen-1yl, unsubstituted phenyl, or X, wherein X isA · US 2013/0281450 A1 · ¶
R10 is aryl or heteroaryl, wherein R10 may be substituted with 1 to 3 substituents designated as R40, R41, and R42 and independently selected from the group consisting of: NO2, NR20R22, halo, C1-C6 alkyl, C1-C6 haloalkyl, —O—C1-C6 alkyl, —O—C1-C6 haloalkyl, C1-C3 alkylene-OH, C1-C3 alkylene-C(O)OH, C1-C3 alkylene-C(O)O—C1-C4 alkyl, C2-C3alkenylene-O—C1-C3alkyl, —NHC(O)—C1-C3 alkyl, —NH—SO2—C1-C3 alkyl, —NH—SO2—C1-C3 haloalkyl, —SO2—NH2, —C(O)—NR20R22, and -L-R12, wherein L isB · US 2014/0275079 A1 · ¶
In certain embodiments, R10 is heteroaryl, which may be substituted with 1 to 3 substituents designated as R40, R41, and R42 and independently selected from the group consisting of: NO2, NR20R22, halo, C1-C6 alkyl, C1-C6 haloalkyl, —O—C1-C6 alkyl, —O—C1-C6 haloalkyl, C1-C3 alkylene-OH, C1-C3 alkylene-C(O)OH, C1-C3 alkylene-C(O)O—C1-C4 alkyl, C2-C3alkenylene-O—C1-C3alkyl, —NHC(O)—C1-C3 alkyl, —NH—SO2—C1-C3 alkyl, —NH—SO2—C1-C3 haloalkyl, —SO2—NH2, —C(O)—NR20R22, and -L-R12, whB · US 2014/0275079 A1 · ¶
R12 is NR16R18, halo, hydroxyl, C1-C3 alkyl, C1-C3 alkylene-aryl, C1-C3 alkylene-O-aryl, —S-aryl, —O—C2-C3 alkylene-aryl, —NR16—SO2—NR18—C1-C3 alkyl, —NR16—SO2—NR18—C1-C3 haloalkyl, —NR16—SO2—C1-C3 alkyl, —NR16—SO2—C1-C3 haloalkyl, SO2—NR16R18, SO2—C1-C3alkyl, —O—C1-C3 alkyl, —C(O)—O—C1-C3 alkyl, —C(O)—OH, —C(O)—NR16R18, —C(O)—NH(C1-C3 haloalkyl), —C(O)—NH(C1-C3 alkylene-heterocycloalkyl), —C(O)—NH(heteroaryl), NH—C(O)—C1-C3 alkyl, NH—C(O)-heteroaryl, heterocycloalkyl, —O—C1-A · US 2013/0281450 A1 · ¶
In certain embodiments, R10 is phenyl which may be substituted with 1 to 3 substituents designated as R40, R41, and R42 and independently selected from the group consisting of: NO2, NR20R22, halo, C1-C6 alkyl, C1-C6 haloalkyl, —O—C1-C6 alkyl, —O—C1-C6 haloalkyl, C1-C3 alkylene-OH, C1-C3 alkylene-C(O)OH, C1-C3 alkylene-C(O)O—C1-C4 alkyl, C2-C3alkenylene-O—C1-C3alkyl, —NHC(O)—C1-C3 alkyl, —NH—SO2—C1-C3 alkyl, —NH—SO2—C1-C3 haloalkyl, —SO2—NH2, —C(O)—NR20R22, and -L-R12, whereinB · US 2014/0275079 A1 · ¶
R15, R16, and R17 are independently selected from the group consisting of: OH, CN, halo, C1-C3 alkyl, C1-C3 haloalkyl, —O—C1-C3 alkyl, —O—C1-C3 haloalkyl, —C1-C3 alkylene-OH, —C1-C3 alkylene-C(O)O—C1-C3 alkyl, —C(O)—C1-C4 alkyl, —C(O)OC1-C4 alkyl, —C(O)NH—C1-C3 alkylene-NR30R32, —C(O)NR30R32, —O—C1-C4 alkyl-NR30N32, —NR30R32, —NHC(O)O—C1-C4 alkyl, —NH—S(O)2—C1-C3 alkyl, —NH—S(O)2—C1-C3 haloalkyl, —S(O)2—C1-C3 alkyl, aryl, —O-aryl, —C1-C3 alkylene-aryl, C3-C6 cycloalkyl, heterB · US 2014/0275079 A1 · ¶
R12 is selected from the group consisting of: C1-C6 alkyl, C1-C6 haloalkyl, C3-C10 cycloalkyl, 3 to 8 membered heterocycloalkyl, 5 to 12 membered heteroaryl, and aryl, which may be substituted with one, two, or three substituents designated R15, R16, and R17;B · US 2014/0275079 A1 · ¶
R8 and R9 are each independently selected from hydrogen and C1-C4 alkyl; and R16 and R18 are each independently selected from hydrogen and C1-C3 alkyl.A · US 2013/0281450 A1 · ¶
R20 and R22 are independently selected from the group consisting of H and C1-C6 alkyl; and R30 and R32 are independently selected from the group consisting of H and C1-C4alkyl.B · US 2014/0275079 A1 · ¶
An empty cell means only that no passage was reproduced there.
Thus, compounds that inhibit the binding of BET family bromodomains to their cognate acetylated lysine proteins are being pursued for the treatment of cancer, inflammatory diseases, kidney diseases, diseases involving metabolism or fat accumulation, and some viral infections, as well as for providing a method for male contraception.A · US 2013/0281450 A1 · ¶ 2
Accordingly, there is an ongoing medical need to develop new drugs to treat these indications.A · US 2013/0281450 A1 · ¶ 2
Thus, compounds that inhibit the binding of BET family bromodomains to their cognate acetylated lysine proteins are being pursued for the treatment of cancer, inflammatory diseases, kidney diseases, diseases involving metabolism or fat accumulation, and some viral infections, as well as for providing a method for male contraception.B · US 2014/0275079 A1 · ¶ 1
Accordingly, there is an ongoing medical need to develop new drugs to treat these indications.B · US 2014/0275079 A1 · ¶ 1
patent.fyi, US 2026/0356857 A1, claim 1, first published 2026-11-20T08:11:50-05:00, https://patent.fyi/US20260356857/, SHA-256 bbd6a629aef9aa752a1f98f01600d586a04fcb128944831c01c21641fcb4ee16